medigraphic.com

2009, Número 1

<< Anterior Siguiente >>

Rev Med Inst Mex Seguro Soc 2009; 47 (1)


Quimiotaxis y enfermedad

Rojas-Dotor S, Pérez-Ramos J, Rico-Rosillo MG

Idioma: Español
Referencias bibliográficas: 40
Paginas: 51-56
Archivo PDF: 40.92 Kb.


RESUMEN

La quimiotaxis es la habilidad de las células vivas para determinar la dirección de su locomoción a lo largo de un gradiente de concentración de sustancias atractantes o repelentes. En la presente investigación se describen sustancias como el complemento y sus componentes, así como otros mediadores solubles que causan quimiotaxis (citocinas/quimiocinas) y su relación con algunas enfermedades.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Abbas AK, Lichtman AH. Cellular and molecular immunology. Fifth edition. Philadelphia: Saunders Elsevier; 2004. p. 243-274.

  2. Wilkinson PC. Chemotaxis and inflammation. London, UK: Churchill Livingstone; 1982. p. 1-34.

  3. Chollet-Martin S, Gougerot-Pocidalo MA. Hereditary polymorphonuclear neutrophil deficiencies. Transfus Clin Biol 2000;7(6):533-539.

  4. Roitt IM. Immunology. Fifth edition. London, UK: Mosby; 1998. p. 61-69.

  5. Schiffman E. Leukocyte chemotaxis. Annu Rev Physiol 1982;44:553-568.

  6. Snyderman R, Goetzl EJ. Molecular and cellular mechanisms of leukocyte chemotaxis. Science 1981;213(4510):830-837.

  7. Kobayashi K. Adhesion molecules and leukocyte functions. Rinsho Byori 1995;43(7):665-668.

  8. Prieschl EE, Kulmburg PA, Baumruker T. The nomenclature of chemokines. Int Arch Allergy Immunol 1995;107(4):475-483.

  9. Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995;182(4):1169- 1174.

  10. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220(4597):568-575.

  11. La Rosa GJ, Thomas KM, Kaufmann ME, Mark R, White M, Taylor L, et al. Amino terminus of the interleukin-8 receptor is a major determinant of receptor subtype specificity. J Biol Chem 1992;267(35):25402-25406.

  12. Leonard EJ, Skeel A, Yoshimura T, Rankin J. Secretion of monocyte chemoattractant protein-1 (MCP-1) by human mononuclear phagocytes. Adv Exp Med Biol 1993;351:55-64.

  13. Gerish G. Chemotaxis in Dictyostellium. Ann Rev Physiol 1982;44:535-552.

  14. Bullard DC. Adhesion molecules in inflammatory diseases: insights from knockout mice. Immunol Res 2002;26(1-3):27-33.

  15. Johnston A, Gudjonsson J, Sigmunsdottir H, Ludviksson B, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005;114(2):154-163.

  16. Yonekawa K, Harlan J. Targeting leukocyte integrins in human diseases. J Leukoc Biol 2005;77(2):129-140.

  17. Bunting M, Harris ES, McIntyre TM, Prescott SM, Zimmerman GA. Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving beta 2 integrins and selectin ligands. Curr Opin Hematol 2002;9(1):30-35.

  18. Ward DM, Shiflett SL, Kaplan J. Chediak-Higashi syndrome: a clinical and molecular view of a rare lysosomal storage disorder. Curr Mol Med 2002;(5)2:469-477.

  19. Boocock Gr, Morrison JA, Popovic M, Richards N, Ellio L, Durrie PR, et al. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet 2003;33(1):97-101.

  20. Gerard C, Hugli TE. Identification of classical anaphylatoxin as the C5a molecule: evidence of a modulator role for the olysaccharide united in human des-arg 74 C5a. Proc Natl Acad Sci 1981; 78(3):1833-1837.

  21. Marder SR, Chenoweth DE, Goldstein IM, Pérez HD. Chemotactic response of human peripheral blood monocyte to the complement-derived C5ades- Arg. J Immunol 1985;134(5):3325-3331.

  22. Kolakowski LF Jr, Lu B, Gerard C, Gerard NP. Probing the “message: address” sites for chemoattractant binding to the C5a receptor. Mutagenesis of hydrophilic and proline residues within the transmembrane segments. J Biol Chem 1995;270 (30):18077-18082.

  23. FaIk W, Leonard EJ. Human monocyte chemotaxis: migrating cells are a subpopulation with multiple chemotaxin specificities on each cell. Infect Immunol 1980;29(3):953-959.

  24. Daffern PJ, Pfeifer PH, Ember JA, HugIi TE. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 1995 181(6):2119-2127.

  25. Mrowietz U, Jurgens G. A method for the determination of leukocyte migration for large sample numbers by automated densitometry quantification. J Biochem Biophys Methods 1995;30(1):49-58.

  26. Altman L, Snyderman R, Oppenheim J, Mergenhagen S. A human mononuclear leukocyte chemotatic factor. Characterization specificity and kinetics of production by homologous leukocytes. J Immunol 1973;110(3):801-810.

  27. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999;286(5447): 2098-2102.

  28. Nikel R, Beck LA, Stellato C, Schleimer R. Chemokines and allergic disease. J Allergy Clin Immunol 1999;104(4 Pt 1):723-742.

  29. Kraver T, Vilcek J, Oppenheim JJ. Proinflammatory cytokines. En: Paul WE, editor. Fundamental immunology. Fourth edition. Philadelphia: Lippincott Raven; 1999. p. 775-811.

  30. Ip W, Wong CK, Wang CB, Tian YP, Lam CW. Interleukin-3, -5, and granulocyte macrophage colony-stimulating factor induce adhesion and chemotaxis of human eosinophils via p38 mitogenactivated protein kinase and nuclear factor kappa. Immunopharmacol Immunotoxicol 2005;27(3): 371-393.

  31. Randolph D, Huang G, Carruthers C, Bromley L, Chaplin D. The role of CCR7 in Th1 and TH2 cell localization and delivery of B cell help in vivo. Science 1999;286(5447):2159-2162.

  32. Loetscher P, Ugoccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391(6665):344-345.

  33. Zingoni A, Soto H, Hedrick JA, Stoppacciaro A, Storlarzzi CT, Sinigaglia F, et al. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol 1998;161(2):547-551.

  34. Ying S, Humbert M, Barkans J, Corrigan CJ, Pfister R, Menz G, et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1997;158(7):3539-3544.

  35. Lai CK, Ho SS, Chan CH, Leung R, Lai KN. Gene expression of interleukin-3 and granulocyte macrophage colony-stimulating factor in circulating CD4+ T cells in acute severe asthma. Clin Exp Allergy 1996;26(2):138-146.

  36. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17(3):138-146.

  37. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338(7):436-445.

  38. Berin MC, Eckmann L, Broide DH, Kagnoff MF. Regulated production of the helper 2-type T cell chemoattractant TARC by human bronchial epithelial cells in vitro and in human lung xenografts. Am J Respir Cell Mol Biol 2001;24(4):382-389.

  39. Lazcano MD, Negrete GMC, Montes VAR, Valencia ME, García-Sancho FC, Franco MF, et al. La quimiocina regulada activada del timo (TARC) se libera en las vías aéreas de pacientes asmáticos. Rev Inst Nal Enf Resp Mex 2002;15(4):201-205.

  40. Cano Londoño NF, Montoya-Guarin CJ. Las quimioquinas: citocinas proinflamatorias y reguladoras del tráfico celular. Iatreia 2001;14(1):57-72.




2020     |     www.medigraphic.com